Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Double-Masked, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil

Trial Profile

A Multi-Center, Double-Masked, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs Phenylephrine/tropicamide (Primary)
  • Indications Mydriasis
  • Focus Diagnostic use; Registrational
  • Acronyms MIST-2
  • Sponsors Eyenovia
  • Most Recent Events

    • 06 Feb 2019 Accoding to an Eyenovia media release, the company expects to file NDA in Q1 2020.
    • 06 Feb 2019 Accoding to an Eyenovia media release, the company expects to announce results in Q1 2020.
    • 30 Jan 2019 Accoding to an Eyenovia media release, the company expects to announce topline data from the study in short order.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top